Destruction of Myc by ubiquitin‐mediated proteolysis: cancer‐associated and transforming mutations stabilize Myc

The human proto‐oncogene c‐myc encodes a highly unstable transcription factor that promotes cell proliferation. Although the extreme instability of Myc plays an important role in preventing its accumulation in normal cells, little is known about how Myc is targeted for rapid destruction. Here, we have investigated mechanisms regulating the stability of Myc. We show that Myc is destroyed by ubiquitin‐mediated proteolysis, and define two elements in Myc that oppositely regulate its stability: a transcriptional activation domain that promotes Myc destruction, and a region required for association with the POZ domain protein Miz‐1 that stabilizes Myc. We also show that Myc is stabilized by cancer‐associated and transforming mutations within its transcriptional activation domain. Our data reveal a complex network of interactions regulating Myc destruction, and imply that enhanced protein stability contributes to oncogenic transformation by mutant Myc proteins.

[1]  M. Raffeld,et al.  A link between increased transforming activity of lymphoma-derived MYC mutant alleles, their defective regulation by p107, and altered phosphorylation of the c-Myc transactivation domain , 1995, Molecular and cellular biology.

[2]  D. Beach,et al.  Cdc25 cell-cycle phosphatase as a target of c-myc , 1996, Nature.

[3]  S. Elledge,et al.  The role of protein stability in the cell cycle and cancer. , 1998, Biochimica et biophysica acta.

[4]  A. Levine,et al.  Regulation of the cellular p53 tumor antigen in teratocarcinoma cells and their differentiated progeny , 1982, Molecular and cellular biology.

[5]  P. Mora,et al.  Quantitation of a 55K cellular protein: similar amount and instability in normal and malignant mouse cells , 1982, Molecular and cellular biology.

[6]  R. Davis,et al.  A phosphorylation site located in the NH2-terminal domain of c-Myc increases transactivation of gene expression. , 1991, The Journal of biological chemistry.

[7]  A. Shvarts,et al.  Degradation of E2F by the ubiquitin-proteasome pathway: regulation by retinoblastoma family proteins and adenovirus transforming proteins. , 1996, Genes & development.

[8]  A. Ciechanover,et al.  Basal and human papillomavirus E6 oncoprotein-induced degradation of Myc proteins by the ubiquitin pathway. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[9]  D. Chowdary,et al.  Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway , 1994, Molecular and cellular biology.

[10]  B. Lutterbach,et al.  Hierarchical phosphorylation at N-terminal transformation-sensitive sites in c-Myc protein is regulated by mitogens and in mitosis , 1994, Molecular and cellular biology.

[11]  W. Herr,et al.  Differential transcriptional activation by Oct-1 and Oct-2: Interdependent activation domains induce Oct-2 phosphorylation , 1990, Cell.

[12]  A. Goldberg,et al.  Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules , 1994, Cell.

[13]  R. Eisenman,et al.  Proteins encoded by the human c-myc oncogene: differential expression in neoplastic cells , 1984, Molecular and cellular biology.

[14]  I. Magrath,et al.  Point mutations in the c–Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas , 1993, Nature Genetics.

[15]  M. Hochstrasser.  Ubiquitin-dependent protein degradation. , 1996, Annual review of genetics.

[16]  A. Vartanian,et al.  c‐Raf kinase binds to N‐terminal domain of c‐Myc , 1997, FEBS letters.

[17]  A. Varshavsky,et al.  The ubiquitin system. , 1997, Trends in biochemical sciences.

[18]  T. Kunkel.  Rapid and efficient site-specific mutagenesis without phenotypic selection. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[19]  I. Verma,et al.  Viral and cellular fos proteins: A comparative analysis , 1984, Cell.

[20]  L. Staszewski,et al.  Ubiquitin-dependent c-Jun degradation in vivo is mediated by the δ domain , 1994, Cell.

[21]  G. Klein,et al.  Phosphorylation sites mapping in the N-terminal domain of c-myc modulate its transforming potential. , 1993, Oncogene.

[22]  A Ciechanover,et al.  Degradation of nuclear oncoproteins by the ubiquitin system in vitro. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[23]  A. Papavassiliou,et al.  Targeted degradation of c-Fos, but not v-Fos, by a phosphorylation-dependent signal on c-Jun. , 1992, Science.

[24]  L. Staszewski,et al.  Ubiquitin-dependent c-Jun degradation in vivo is mediated by the delta domain. , 1994, Cell.

[25]  J. Woodgett,et al.  Site-specific modulation of c-Myc cotransformation by residues phosphorylated in vivo. , 1994, Oncogene.

[26]  C. Busch,et al.  myc Boxes, Which Are Conserved in myc Family Proteins, Are Signals for Protein Degradation via the Proteasome , 1998, Molecular and Cellular Biology.

[27]  E. Flemington,et al.  Regulation of E2F through ubiquitin-proteasome-dependent degradation: stabilization by the pRB tumor suppressor protein. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[28]  D. Livingston,et al.  The retinoblastoma gene product protects E2F-1 from degradation by the ubiquitin-proteasome pathway. , 1996, Genes & development.

[29]  A. Gruhler,et al.  The PRE4 gene codes for a subunit of the yeast proteasome necessary for peptidylglutamyl-peptide-hydrolyzing activity. Mutations link the proteasome to stress- and ubiquitin-dependent proteolysis. , 1993, The Journal of biological chemistry.

[30]  Winship Herr,et al.  Basal promoter elements as a selective determinant of transcriptional activator function , 1995, Nature.

[31]  R. Eisenman,et al.  Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. , 1991, Science.

[32]  M. Groudine,et al.  Control of c-myc regulation in normal and neoplastic cells. , 1991, Advances in cancer research.

[33]  R. Bernards,et al.  Functional Analysis of Burkitts Lymphoma Mutant c-Myc Proteins (*) , 1996, The Journal of Biological Chemistry.

[34]  J. Barrett,et al.  An amino-terminal c-myc domain required for neoplastic transformation activates transcription , 1990, Molecular and cellular biology.

[35]  Mike Tyers,et al.  Cdc53 Targets Phosphorylated G1 Cyclins for Degradation by the Ubiquitin Proteolytic Pathway , 1996, Cell.

[36]  Dirk Bohmann,et al.  Reduced Ubiquitin-Dependent Degradation of c-Jun After Phosphorylation by MAP Kinases , 1997, Science.

[37]  M. Henriksson,et al.  Proteins of the Myc network: essential regulators of cell growth and differentiation. , 1996, Advances in cancer research.

[38]  S. Burley,et al.  Radical mutations reveal TATA-box binding protein surfaces required for activated transcription in vivo. , 1996, Genes & development.

[39]  B. Futcher,et al.  p34Cdc28-mediated control of Cln3 cyclin degradation , 1995, Molecular and cellular biology.

[40]  K. Alitalo,et al.  Repression of cyclin D1: a novel function of MYC. , 1994, Molecular and cellular biology.

[41]  S. Jentsch,et al.  Multiple ubiquitin-conjugating enzymes participate in the in vivo degradation of the yeast MATα2 repressor , 1993, Cell.

[42]  R. Müller,et al.  Yeast vectors for the controlled expression of heterologous proteins in different genetic backgrounds. , 1995, Gene.

[43]  E. Nishida,et al.  Degradation of c-Fos by the 26S proteasome is accelerated by c-Jun and multiple protein kinases , 1995, Molecular and cellular biology.

[44]  P. Baeuerle,et al.  A proteasome inhibitor prevents activation of NF‐kappa B and stabilizes a newly phosphorylated form of I kappa B‐alpha that is still bound to NF‐kappa B. , 1994, The EMBO journal.

[45]  M. Raffeld,et al.  Mutations in the coding region of c-MYC in AIDS-associated and other aggressive lymphomas. , 1994, Cancer research.

[46]  G. Evan,et al.  Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max , 1992, Nature.

[47]  Liang Zhu,et al.  Interaction of c‐Myc with the pRb‐related protein p107 results in inhibition of c‐Myc‐mediated transactivation. , 1994, The EMBO journal.

[48]  T. Graf,et al.  Quail embryo fibroblasts transformed by four v‐myc‐containing virus isolates show enhanced proliferation but are non tumorigenic. , 1983, The EMBO journal.

[49]  G. Carmichael,et al.  An alternative pathway for gene regulation by Myc , 1997, The EMBO journal.

[50]  W. Herr,et al.  Promoter-selective activation domains in Oct-1 and Oct-2 direct differential activation of an snRNA and mRNA promoter , 1992, Cell.

[51]  J L Cleveland,et al.  The ornithine decarboxylase gene is a transcriptional target of c-Myc. , 1993, Proceedings of the National Academy of Sciences of the United States of America.